Cite
HARVARD Citation
Kim, S. et al. (n.d.). 2597 Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC). European journal of cancer. pp. S510-. [Online].